May 15th 2024
For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
A First In-Human Study of Novel PI3K Inhibitor IPI-549 in Patients With Advanced Solid Tumors
May 24th 2017Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.
Watch
Dr. Kaufman Discusses Durable Responses to Avelumab in Merkel Cell Carcinoma
May 18th 2017Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.
Watch
Systemic Therapy Under Consideration for Melanoma-Associated Brain Metastases
May 17th 2017Outcomes have significantly improved for patients with melanoma in the wake of newer targeted treatments. Yet, brain metastases from melanoma remain a significant unmet need, with up to 60% of patients with advanced melanoma developing brain metastases.
Read More
Benefit of Encorafenib/Binimetinib Combo in Melanoma Confirmed in Updated Findings
May 11th 2017The BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib reduced the risk of disease progression or death by 23% compared with single-agent encorafenib for patients with <em>BRAF</em>-mutant melanoma.
Read More
BGB324 With Pembrolizumab or Dabrafenib/Trametinib in Melanoma
April 21st 2017Oddbjørn Straume, MD, PhD, associate professor, department of Clinical Science, Haukeland University Hospital, discusses a study investigating BGB324 with pembrolizumab or dabrafenib/trametinib in patients with advanced non-resectable or metastatic melanoma.
Watch
Intriguing Biomarker Results in Study of Avelumab in Merkel Cell Carcinoma
April 18th 2017Responses to treatment with avelumab monotherapy can increase in certain subtypes of patients with metastatic Merkel cell carcinoma, per an analysis of the phase II JAVELIN Merkel 200 trial that was presented during the ASCO-SITC Clinical Immuno-Oncology Symposium.
Read More
Treating Melanoma After Immunotherapy and Targeted Therapies
April 17th 2017Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses options for treating melanoma after the use of targeted therapies and immunotherapy.
Watch
Higher Dose of Ipilimumab Improves Survival, But Increases Toxicities in Advanced Melanoma
April 12th 2017According to results from a randomized, double-blind, phase III study, patients with stage III or IV melanoma assigned to 10 mg/kg ipilimumab lived longer than patients assigned to a lower dose of the anti-CTLA-4 anticlonal antibody, but at the cost of greater toxicity.
Read More
Ideal Treatment for Melanoma in the Adjuvant Setting
April 11th 2017Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the ideal therapy for melanoma in the adjuvant setting.
Watch
Encouraging Early Signal Seen With Addition of Coxsackievirus to Ipilimumab in Melanoma
April 7th 2017Adding a formulation of the Coxsackievirus A21 to ipilimumab yielded an overall response rate of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.
Read More
Novel RAF Inhibitor BGB-283 Active in Multiple Tumor Types
April 6th 2017BGB-283, a novel agent that targets <em>RAS/RAF</em>-mutated tumors, demonstrated activity across a variety of tumor types, according to the results of a preliminary clinical evaluation presented at the 2017 AACR Annual Meeting.
Read More
Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma
April 6th 2017Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma.
Watch